

### REMARKS

The claims have been limited to cancer antigen derived peptides which are coupled to Pan DR binding peptides. It will be noted that the claim is limited to only those peptides which are actually immunogenic. The elected species is found on page 7 of Table 3, the 17th peptide down which is derived from MAGE. The epitope begins at position 2 of this peptide. It is believed that the claims are consistent with the restriction requirement as applicants understand it. Claims 130-144 simply spell out all possible combinations of the residue at position 2 and at the C-terminus. The claims that read on the elected species are 128, 129, 137 and 145. Examination on the merits is requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 399632000623. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: March 5, 2001

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125